@article{0038398165dc4a36b3df990de6536f1b,
title = "Clinical and Infection Prevention Applications of Severe Acute Respiratory Syndrome Coronavirus 2 Genotyping: an Infectious Diseases Society of America/American Society for Microbiology Consensus Review Document",
abstract = "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged into a world of maturing pathogen genomics, with more than 2 million genomes sequenced at the time of writing. The rise of more transmissible variants of concern that impact vaccine and therapeutic effectiveness has led to widespread interest in SARS-CoV-2 evolution. Clinicians are also eager to take advantage of the information provided by SARS-CoV-2 genotyping beyond surveillance purposes. Here, we review the potential role of SARS-CoV-2 genotyping in clinical care. The review covers clinical use cases for SARS-CoV-2 genotyping, methods of SARS-CoV-2 genotyping, assay validation and regulatory requirements, and clinical reporting for laboratories, as well as emerging issues in clinical SARS-CoV-2 sequencing. While clinical uses of SARS-CoV-2 genotyping are currently limited, rapid technological change along with a growing ability to interpret variants in real time foretells a growing role for SARS-CoV-2 genotyping in clinical care as continuing data emerge on vaccine and therapeutic efficacy.",
author = "Greninger, {Alexander L.} and Bard, {Jennifer Dien} and Colgrove, {Robert C.} and Graf, {Erin H.} and Hanson, {Kimberly E.} and Hayden, {Mary K.} and Humphries, {Romney M.} and Lowe, {Christopher F.} and Miller, {Melissa B.} and Pillai, {Dylan R.} and Rhoads, {Daniel D.} and Yao, {Joseph D.} and Lee, {Francesca M.}",
note = "Funding Information: D.D.R. has received funding from Cepheid, Cleveland Diagnostics, Luminex, Qiagen, and Talis Biomedical outside the submitted work. D.R.P. has a relationship with Illucidx Inc. outside the submitted work. A.L.G. has received central testing contracts from Abbott Molecular and has received funding from Gilead and Merck outside the submitted work. M.B.M. receives fees and funding from Cepheid, Luminex Molecular Diagnostics, Qiagen, Talis Biomedical, Werfen, Agena Bioscience, Sherlock Biosciences, Abbott Molecular, and ArcBio outside the submitted work. All other authors report no potential conflicts. Publisher Copyright: {\textcopyright} 2022 American Society for Microbiology. All rights reserved.",
year = "2022",
month = jan,
doi = "10.1128/JCM.01659-21",
language = "English (US)",
volume = "60",
journal = "Journal of clinical microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "1",
}